APA (7th ed.) Citation

Fakih, M., Le, D. T., Pedersen, K. S., Shields, A. F., Shah, M. A., Mukherjee, S., . . . Overman, M. J. (2022). First clinical and immunogenicity results including all subjects enrolled in a phase I study of Nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability (dMMR/MSI). Journal of clinical oncology, 40(16_suppl), 2515. https://doi.org/10.1200/JCO.2022.40.16_suppl.2515

Chicago Style (17th ed.) Citation

Fakih, Marwan, et al. "First Clinical and Immunogenicity Results Including All Subjects Enrolled in a Phase I Study of Nous-209, an Off-the-shelf Immunotherapy, with Pembrolizumab, for the Treatment of Tumors with a Deficiency in Mismatch Repair/microsatellite Instability (dMMR/MSI)." Journal of Clinical Oncology 40, no. 16_suppl (2022): 2515. https://doi.org/10.1200/JCO.2022.40.16_suppl.2515.

MLA (9th ed.) Citation

Fakih, Marwan, et al. "First Clinical and Immunogenicity Results Including All Subjects Enrolled in a Phase I Study of Nous-209, an Off-the-shelf Immunotherapy, with Pembrolizumab, for the Treatment of Tumors with a Deficiency in Mismatch Repair/microsatellite Instability (dMMR/MSI)." Journal of Clinical Oncology, vol. 40, no. 16_suppl, 2022, p. 2515, https://doi.org/10.1200/JCO.2022.40.16_suppl.2515.